Alvimopan, a selective peripherally acting mu-opioid antagonist.
Alvimopan is a novel, peripherally acting mu-opioid antagonist that is being developed for the management of acute postoperative ileus and for the reversal of the delayed gastrointestinal and colonic transit that result in symptoms such as constipation, nausea and motility disorders in patients treated with opiate analgesics. There is a clinical need for effective medications for the treatment of postoperative ileus and opiate-induced constipation and other motility disorders. This review addresses the basic and applied pharmacology and current evidence for the use of the medication, alvimopan, in clinical gastroenterology.
Camilleri
M
M
Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. camilleri.michael@mayo.edu
D000818:Animals; D003248:Constipation / Q000188:drug therapy; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D045823:Ileus / Q000188:drug therapy*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D011183:Postoperative Complications / Q000188:drug therapy*; D017450:Receptors, Opioid, mu / Q000187:drug effects
D009292:Narcotic Antagonists; D010880:Piperidines; D017450:Receptors, Opioid, mu; C419502:alvimopan